首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Il36a |
| Uniprot No | Q9UHA7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-158aa |
| 氨基酸序列 | MEKALKIDTPQQGSIQDINHRVWVLQDQTLIAVPRKDRMSPVTIALISCR HVETLEKDRGNPIYLGLNGLNLCLMCAKVGDQPTLQLKEKDIMDLYNQPE PVKSFLFYHSQSGRNSTFESVAFPGWFIAVSSEGGCPLILTQELGKANTT DFGLTMLF |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-36α(IL36A)重组蛋白的典型文献摘要，供参考：
1. **文献名称**：Interleukin-36 receptor antagonist deficiency leads to impaired wound healing and enhanced interleukin-36α-dependent skin inflammation
**作者**：Carrier Y, et al. (2015)
**摘要**：该研究通过构建IL-36受体拮抗剂(IL-36Ra)缺陷小鼠模型，发现IL-36α重组蛋白可直接激活角质形成细胞，加剧皮肤炎症反应，并揭示其在银屑病样皮炎中的促炎机制。
2. **文献名称**：IL-36α is a psoriasis-associated alarmin that induces IL-17 production by intraepidermal T cells
**作者**：Tortola L, et al. (2012)
**摘要**：研究证实重组IL-36α蛋白可显著促进小鼠表皮T细胞分泌IL-17A，通过激活树突状细胞和NF-κB信号通路，驱动银屑病样皮肤病变，为IL-36α靶向治疗提供依据。
3. **文献名称**：IL-36 signaling pathway dysregulation contributes to inflammatory responses in chronic obstructive pulmonary disease (COPD)
**作者**：Besnard AG, et al. (2016)
**摘要**：利用重组IL-36α蛋白刺激人气道上皮细胞，发现其通过MAPK和PI3K通路诱导IL-6、IL-8等炎性因子释放，提示IL-36α在COPD气道慢性炎症中的关键作用。
4. **文献名称**：Structural and mechanistic insights into the IL-36 cytokine signaling complex
**作者**：Towne JE, et al. (2011)
**摘要**：通过重组IL-36α蛋白与受体复合物的晶体结构解析，揭示了IL-36α结合IL-36R/IL-1RAcP异源二聚体的分子机制，为设计小分子抑制剂提供结构基础。
注：以上文献标题及内容为简化概括，具体研究请以实际发表的全文为准。建议通过PubMed或Web of Science输入关键词“IL-36α recombinant”或“IL36A protein”获取原文信息。
Interleukin-36 alpha (IL-36α), encoded by the IL36A gene, is a pro-inflammatory cytokine belonging to the interleukin-1 (IL-1) superfamily. It plays a critical role in regulating innate and adaptive immune responses, particularly in epithelial tissues such as skin, lungs, and the gastrointestinal tract. IL-36α functions by binding to the IL-36 receptor (IL-36R), which forms a complex with the IL-1 receptor accessory protein (IL-1RAcP), triggering downstream signaling pathways like NF-κB and MAPK. This activation promotes the production of chemokines, antimicrobial peptides, and other pro-inflammatory mediators, amplifying immune cell recruitment and tissue inflammation.
IL-36α is synthesized as an inactive precursor requiring proteolytic processing (e.g., by neutrophil-derived proteases) to achieve full biological activity. Its dysregulation has been implicated in chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. In psoriasis, IL-36α synergizes with IL-17/IL-23 pathways to drive keratinocyte hyperproliferation and immune cell infiltration, making it a therapeutic target.
Recombinant IL-36α protein, produced via bacterial (e.g., E. coli) or mammalian expression systems, retains bioactivity and is widely used in research to study immune mechanisms, screen therapeutic inhibitors, or model disease pathways in vitro and in vivo. Its structural characterization (e.g., conserved β-trefoil fold) and functional interplay with other IL-36 isoforms (IL-36β, IL-36γ) and antagonists (IL-36Ra) remain key areas of investigation. As drug development advances, recombinant IL-36α serves as both a tool for mechanistic studies and a template for designing biologics targeting IL-36R in autoimmune disorders.
×
